Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors

European Journal of Medicinal Chemistry
2017.0

Abstract

Angiogenesis is modulated by a multitude of pro-angiogenic factors including VEGFR-2, Tie-2, and EphB4. Moreover, their crosstalk also had been well elaborated. We have identified several diarylurea-based VEGFR-2 inhibitors as potential anti-angiogenesis agents. As a continuation to our previous research, two series of diaryl malonamide and diaryl thiourea derivatives have been developed as multiplex VEGFR-2/Tie-2/EphB4 inhibitors. Interestingly, the biological evaluation indicated that several compounds bearing trifluoromethyl or trifluoromethoxyl exhibited promising multiplex inhibition against angiogenesis-related VEGFR-2, Tie-2, and EphB4. The representative compound (18a) displayed both potent multi-targeted RTK inhibition and considerable antiproliferative activities against human umbilical vein endothelial cells (EA.hy926). These results will contribute to the discovery of novel muti-targeted anti-angiogenesis agents.

Knowledge Graph

Similar Paper

Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors
European Journal of Medicinal Chemistry 2017.0
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1 H -indazole-3-amine as multi-target RTKs inhibitors
European Journal of Medicinal Chemistry 2017.0
Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs
European Journal of Medicinal Chemistry 2019.0
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol
European Journal of Medicinal Chemistry 2019.0
Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4
European Journal of Medicinal Chemistry 2017.0
Novel multitarget inhibitors with antiangiogenic and immunomodulator properties
European Journal of Medicinal Chemistry 2019.0
Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors
Bioorganic & Medicinal Chemistry 2016.0
A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis
Journal of Medicinal Chemistry 2016.0
Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors
Bioorganic & Medicinal Chemistry 2015.0
Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: Exploration of diverse hinge-binding fragments
Bioorganic & Medicinal Chemistry 2015.0